Abstract:Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable treatment responses which have revolutionized oncology. However, despite over 40% of cancer patients being eligible to receive immunotherapy, only 12% of patients gain benefit. A key to understanding what differentiates treatment response from non-response is better defining the role of the innate immune system in anti-tumor immunity and immune tolerance. Teleologically, myeloid cells, including macrophages, dendritic cells, monocytes, and neutrophils, initiate a response to invading pathogens and tissue repair after pathogen clearance is successfully accomplished. However, in the tumor microenvironment (TME), these innate cells are hijacked by the tumor cells and are imprinted to furthering tumor propagation and dissemination. Major advancements have been made in the field, especially related to the heterogeneity of myeloid cells and their function in the TME at the single cell level, a topic that has been highlighted by several recent international meetings including the 2021 China Cancer Immunotherapy workshop in Beijing. Here, we provide an up-to-date summary of the mechanisms by which major myeloid cells in the TME facilitate immunosuppression, enable tumor growth, foster tumor plasticity, and confer therapeutic resistance. We discuss ongoing strategies targeting the myeloid compartment in the preclinical and clinical settings which include: (1) altering myeloid cell composition within the TME; (2) functional blockade of immune-suppressive myeloid cells; (3) reprogramming myeloid cells to acquire pro-inflammatory properties; (4) modulating myeloid cells via cytokines; (5) myeloid cell therapies; and (6) emerging targets such as Siglec-15, TREM2, MARCO, LILRB2, and CLEVER-1. There is a significant promise that myeloid cell-based immunotherapy will help advance immuno-oncology in years to come.

Targeting tumor-associated myeloid cells for cancer immunotherapy

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Targeting polymorphonuclear myeloid‐derived suppressor cells in the immunosuppressive tumor microenvironment for cancer immunotherapy

Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer

Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy

Targeting the Depletion of M2 Macrophages: Implication in Cancer Immunotherapy

Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies

Potential therapeutic targets in myeloid cell therapy for overcoming chemoresistance and immune suppression in gastrointestinal tumors

Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment

Targeting MHC-I inhibitory pathways for cancer immunotherapy

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy

Targeting myeloid cells in the tumor sustaining microenvironment

Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1

Novel Tumor Immunotherapy: Targeting Dysfunctional Antigen Presenting Cells.

Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicity

Targeting the MHC-I endosomal-lysosomal trafficking pathway in cancer: From mechanism to immunotherapy

Targeting tumor-associated macrophages for cancer treatment

Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer

Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer